Clinical ResearchAtherosclerosisThe Cost-Effectiveness of C-Reactive Protein Testing and Rosuvastatin Treatment for Patients With Normal Cholesterol Levels
Atherosclerosis
Under an Elsevier user license
open archive
Key Words
cost-effectiveness
hs-CRP
statin
Abbreviations and Acronyms
hs-CRP
high-sensitivity C-reactive protein
LDL
low-density lipoprotein
MI
myocardial infarction
QALY
quality-adjusted life year
Cited by (0)
This study was not funded by any external source, and no author receives any personal compensation from any pharmaceutical manufacturer. Dr. Glynn has received salary support for his work on the JUPITER trial through a research grant from AstraZeneca. The authors have no other potential conflicts of interest. The authors are employees of Brigham and Women's Hospital, an institution that holds patents that relate to the use of high-sensitivity C-reactive protein in the evaluation of patients' risk of cardiovascular disease, but the authors do not benefit from these patents.
Copyright © 2011 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.